U.S. Application No.: 10/662,441 Attorney Docket No. 063779-5001-US (Formerly 11438-004-999)

REMARKS

Applicants respectfully request entry of the following remarks, and provisional election. Claims 56-119 are currently pending in this application. Applicants have canceled claims 1-55 without prejudice. Claim 83 has been amended to correct a typographical error and not for reasons related to patentability. Applicants have withdrawn claims 90-119 without prejudice. Applicants reserve the right to file one or more continuation, divisional, or continuation-in-part applications to any canceled or withdrawn subject matter. No new matter has been added by this paper.

According to the office action, the application allegedly contains claims directed to more than one invention. Applicants provisionally elect with traverse Group I, directed to claims 56-89, drawn to methods of treating cancer.

The office action further requires the election of a single compound (or set of compounds). In response to the requirement for election of a single compound or set of compounds, the Applicants elect the anthracyclin class anticancer agents. Particular, compounds that fall within this definition include doxorubicin, daunorubicin, and pirarubicin, which are disclosed in the specification as filed at page 41.

These compounds have the following structures:

U.S. Application No.: 10/662,441 Attorney Docket No. 063779-5001-US (Formerly 11438-004-999)

Pirarubicin

Doxorubicin

Daunorubicin

The lipophilic moiety, which Applicants elect for the Examiner's initial search, is an n-9 C₁₈-monounsaturated alkyl group.

Applicants submit that claims 56-65, 67-76, and 78-89 are readable thereon.

Applicants also advise the Examiner that they have submitted a Power of Attorney and Change of Correspondence Address associated with customer number 09629. Applicants request that the Examiner please forward all future correspondence to the address associated with this customer number.

No fees are believed to be due for this submission; however, should the Patent Office determine otherwise, please charge the required fee to Morgan, Lewis & Bockius LLP Deposit Account 50-0310.

Except for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any necessary fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17, which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-

U.S. Application No.: 10/662,441 Attorney Docket No. 063779-5001-US (Formerly 11438-004-999)

0310. This paragraph is intended to be a Constructive Petition for Extension of Time in accordance with 37 C.F.R. § 1.136(a)(3). The Examiner is invited to telephone the undersigned should she find that an interview might advance the examination of this application.

Respectfully submitted,

Date: June 22, 2007

Dean L. Fanelli (Reg. No. 48,907)

MORGAN, LEWIS & BOCKIUS LLP

Customer No.: 009629

1111 Pennsylvania Avenue, N.W.

Washington, D.C. 20004

(202) 739-3000-phone

(202) 739-3001-fax